Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

Rhea-AI Summary

Clearside Biomedical, Inc. (Nasdaq: CLSD) will report its Q4 and full-year 2022 financial results on March 9, 2023, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company’s financial performance and corporate updates. Clearside specializes in innovative drug delivery methods to the back of the eye, primarily through its SCS Microinjector platform, enhancing treatments for eye diseases. The company’s first product, XIPERE, is available in the U.S. Further details can be found on their website.

Positive

• Upcoming Q4 2022 financial results expected to provide insights into corporate performance.
• The SCS Microinjector platform continues to enable innovative non-surgical treatments for eye diseases.
• XIPERE is commercially available, suggesting successful product development and market entry.

Negative

• None.

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telephone, please register in advance using the link provided in the event listing. The Company suggests participants log in 15 minutes in advance of the event.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its Q4 2022 financial results?

Clearside Biomedical will report its Q4 2022 financial results on March 9, 2023, after market close.

What is the significance of the SCS Microinjector for Clearside Biomedical?

The SCS Microinjector allows for targeted, non-surgical delivery of therapies to the back of the eye, enhancing treatment options for patients.

What product does Clearside Biomedical have available in the U.S.?

Clearside Biomedical's first product, XIPERE, is available for suprachoroidal use in the U.S.

What time is the conference call for Clearside Biomedical's financial results?

The conference call will take place at 4:30 p.m. Eastern Time on March 9, 2023.